Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;157(6):1448-1456.e1.
doi: 10.1053/j.gastro.2019.08.048. Epub 2019 Sep 12.

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease

Miriam B Vos  1 , Lara Dimick-Santos  2 , Ruby Mehta  2 , Stephanie O Omokaro  2 , Johannes Taminiau  3 , Elmer Schabel  4 , David E Kleiner  5 , Peter Szitanyi  6 , Piotr Socha  7 , Jeffrey B Schwimmer  8 , Stephanie Noviello  9 , Debra G Silberg  10 , Richard Torstenson  11 , Veronica Miller  12 , Joel E Lavine  13 ; Liver Forum Pediatric Working Group
Collaborators, Affiliations
Editorial

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease

Miriam B Vos et al. Gastroenterology. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors disclose the following: Dr Vos reports personal fees from AMRA, Bristol Myers Squibb, Boehringer Ingelheim, Intercept, Shire, Mallinrockdt, Novo Nordisk, Target Pharmasolutions and grants from Gemphire, Immuron, Target Pharmasolutions and Resonance Health Ltd. Dr Schwimmer reports ad hoc consulting fees from NovoNordisk and grants from Galmed and Intercept. Stephanie Noviello is a former employee and current stockholder of Bristol-Myers Squibb, and a stockholder of Merck and Johnson & Johnson. Debra G. Silberg is a full-time employee of Takeda Pharmaceutical Company (previously Shire). Richard Torstenson is a former employee of Novo Nordisk A/S Denmark and currently a full-time employee and stockholder of Allergan, UK. Dr Miller is an employee of the Forum for Collaborative Research, which receives contributions from the following companies: AbbVie, Afimmune, Aligos Therapeutics, Allergan, AMRA, AstraZeneca, BMS, Boehringer Ingelheim, Celera (Quest), Celgene, Cirius Therapeutics, Conatus, ConSynance Therapeutics, Covance Owned by LabCorp, CTI Clinical Trial and Consulting Services, Cymabay, Deuterx (Poxel), DiaPharma, Echosens, Eli Lilly, Enanta Pharmaceuticals, ENYO Pharma, Exalenz, Ferring Pharmaceuticals, Fractyl, Genentech, Genfit, Gilead, GSK, HepQuant, HistoIndex Pte Ltd, Humedics GmbH, ICON, Immuron, Intercept Pharmaceuticals, Inventiva Pharma, Janssen, Madrigal Pharmaceuticals, Mallinckrodt Pharmaceuticals, MEDIAN Technologies, MediciNova, Morphic Therapeutic, NGM Biopharmaceuticals, Nordic Bioscience, NorthSea Therapeutics, Novartis, Novo Nordisk, NuSirt, Perspectum Diagnostics, Pfizer, Pliant Therapeutics, ProSciento, Resonance Health, Resoundant, Shire, Syneos Health, Takeda, TARGET PharmaSolutions, VLVBio, Zafgen, and Zealand. Dr Lavine reports ad hoc consulting fees from Merck, Pfizer, Janssen, Allergan, Novartis, NovoNordisk, Viking, Madrigal, Horizon, and Target PharmaSolutions.

Similar articles

See all similar articles

Cited by

  • Perspectives on youth-onset nonalcoholic fatty liver disease.
    Castillo-Leon E, Cioffi CE, Vos MB. Castillo-Leon E, et al. Endocrinol Diabetes Metab. 2020 Sep 17;3(4):e00184. doi: 10.1002/edm2.184. eCollection 2020 Oct. Endocrinol Diabetes Metab. 2020. PMID: 33102800 Free PMC article. Review.
  • Randomized placebo-controlled trial of losartan for pediatric NAFLD.
    Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, Jain AK, Karpen SJ, Lavine JE, Mohammad S, Miriel LA, Molleston JP, Mouzaki M, Sanyal A, Sharkey EP, Schwimmer JB, Tonascia J, Wilson LA, Xanthakos SA; NASH Clinical Research Network. Vos MB, et al. Hepatology. 2022 Aug;76(2):429-444. doi: 10.1002/hep.32403. Epub 2022 Feb 28. Hepatology. 2022. PMID: 35133671 Free PMC article. Clinical Trial.
  • Diagnostic and Treatment Dilemmas in Pediatric NAFLD.
    Rudolph B. Rudolph B. Clin Liver Dis (Hoboken). 2021 Aug 30;18(1):37-39. doi: 10.1002/cld.1085. eCollection 2021 Jul. Clin Liver Dis (Hoboken). 2021. PMID: 34484703 Free PMC article. Review. No abstract available.
  • Advancing the global public health agenda for NAFLD: a consensus statement.
    Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; NAFLD Consensus Consortium. Lazarus JV, et al. Nat Rev Gastroenterol Hepatol. 2022 Jan;19(1):60-78. doi: 10.1038/s41575-021-00523-4. Epub 2021 Oct 27. Nat Rev Gastroenterol Hepatol. 2022. PMID: 34707258 Review.
  • Burden of non-alcoholic steatohepatitis among children with type 2 diabetes mellitus.
    Parlett L, Ma Q, Shi Q, Crawford G, Herrera Scott L, Willey V, Agiro A. Parlett L, et al. Diabetol Metab Syndr. 2021 Apr 21;13(1):47. doi: 10.1186/s13098-021-00665-0. Diabetol Metab Syndr. 2021. PMID: 33883009 Free PMC article.
See all "Cited by" articles

References

    1. Berardis S, Sokal E. Pediatric non-alcoholic fatty liver disease: an increasing public health issue. Eur J Pediatr 2014;173:131–139. - PMC - PubMed
    1. Anderson EL, Howe LD, Jones HE, et al. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One 2015;10:e0140908. - PMC - PubMed
    1. Wah-Kheong C, Khean-Lee G. Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease. Hepatol Int 2013;7:65–71. - PubMed
    1. Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58:593–608. - PubMed
    1. Bedogni G, Miglioli L, Masutti F, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007;46:1387–1391. - PubMed

Publication types